NASDAQ$OPRX

OptimizeRx Corporation · Q3 2023 earnings

Q3 2023 earnings · · Investor relations

Briefing

Reported third quarter results above expectations, driven by momentum in the Dynamic Audience Activation Platform (DAAP) and increased guidance for 2023 and introduced guidance for 2024.

OptimizeRx reported strong third-quarter results, exceeding expectations due to the increased utilization of their Dynamic Audience Activation Platform (DAAP). The company's total DAAP deals for the year reached 16. They also completed the acquisition of Medicx Health after the quarter ended. The company increased its guidance for 2023 and introduced preliminary guidance for 2024.

  • Total revenue reached $16.3 million.
  • GAAP net loss per share was $(0.17).
  • Non-GAAP net income per share was $0.09.
  • Total DAAP deals for the year now stands at 16.

Headline financials

Total Revenue

$16.3M

Previous: $15.1M+8.3%
EPS (adj)

$0.09

Previous: $0.07+28.6%
Capital Expenditures

-$81.8K

Previous: -$64.7K-26.4%
Free Cash Flow

-$2.95M

Previous: -$3.53M+16.5%
Net Income

-$2.87M

Previous: -$3.47M+17.4%
Operating Income

-$3.55M

Previous: -$3.76M+5.4%
Gross Profit

$9.8M

Previous: $9.42M+4.0%
Cash & Equivalents

$63.5M

Previous: $41.3M+53.7%
Total Assets

$124M

Previous: $136M-8.8%
Stock-Based Comp

$3.21M

Previous: $4.28M-25.0%

Revenue & EPS history

OptimizeRx · Revenue · Quarterly

$16.3M

Q3 2023+8.3%vs Q3 2022
Beat estimate in 10 of 15 quarters(67%)
ActualEstimate

Forward guidance

The company is increasing its guidance for 2023 and introducing preliminary guidance for 2024.

Tailwinds

  • Revenue for 2023 is now expected to be between $68 million and $70 million.
  • Adjusted EBITDA for 2023 is expected to be between $3 million and $4 million.
  • OptimizeRx's pre-acquisition business will account for $63 to $65 million of 2023's revenue guidance.
  • Revenue for 2024 is expected to be at least $110 million.
  • Adjusted EBITDA margins for 2024 are expected to be at least 10%.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q3 2023

Historical avgQ3 2023

+1.3%

Avg return

Earnings day

+4.5%

Avg return

5 days after

+5.6%

Avg return

30 days after

55%

30 / 55 earnings

Positive

+51.7%

Q4 2024

Best reaction

-34.5%

Q2 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-22.6%-19.7%-17.5%
Q4 2025-10.5%-11.4%-12.9%
Q3 2025-17.0%-14.7%-24.8%
Q1 2025+20.7%+24.2%+63.6%
Q4 2024+51.7%+99.8%+96.4%
Q3 2024-30.5%-28.1%-14.6%
Q2 2024+1.2%+4.5%-8.9%
Q1 2024+25.0%+20.4%+5.5%
Q4 2023+13.6%+4.9%+20.1%
Q3 2023+13.9%+7.4%+14.1%
Q2 2023-29.3%-32.6%-38.9%
Q1 2023-6.2%-9.1%+2.6%
Q4 2022-14.2%-25.0%-14.5%
Q3 2022+22.2%+51.4%+28.6%
Q2 2022-34.5%-31.6%-33.4%
Q1 2022-2.9%-17.9%-9.9%
Q4 2021+14.0%+2.4%-5.5%
Q3 2021-8.1%-6.6%-36.8%
Q2 2021+20.9%+16.0%+27.7%
Q1 2021+4.4%-11.1%+2.1%
Q4 2020+0.8%-0.2%-17.4%
Q3 2020+6.9%+13.5%+32.6%
Q2 2020+11.0%+10.2%+21.8%
Q1 2020+11.5%+16.0%+33.6%
Q4 2019-26.0%+3.6%-36.8%
Q3 2019-17.6%-19.5%-30.1%
Q2 2019+2.6%+0.8%+13.9%
Q1 2019+18.5%+22.8%+17.7%
Q4 2018+1.1%-0.2%+22.6%
Q3 2018-4.6%-0.7%-5.7%
Q2 2018+15.9%+23.4%+26.7%
Q1 2018+0.0%+7.1%+32.5%
Q4 2017+0.0%+10.7%+14.5%
Q3 2017+15.4%+25.6%+33.3%
Q2 2017+16.4%+9.1%+15.5%
Q1 2017+10.3%+20.6%+17.6%
Q4 2016-10.6%+7.9%+1.3%
Q3 2016-13.3%+0.0%-14.3%
Q2 2016+0.9%+0.0%-3.5%
Q4 2015+3.2%
Q2 2015-3.2%
Q4 2014+2.3%
Q3 2014-4.3%
Q2 2014+8.3%
Q4 2012+11.2%
Q2 2012+5.4%
Q1 2012-10.4%
Q4 2011+0.0%
Q3 2011-1.9%
Q2 2011+20.0%
Q1 2011-15.2%
Q4 2010+0.0%
Q3 2010+15.0%
Q2 2010-10.7%
Q1 2010+1.6%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro